Show Summary Details
Page of

Charcot-Marie-Tooth Disease and Pregnancy 

Charcot-Marie-Tooth Disease and Pregnancy
Charcot-Marie-Tooth Disease and Pregnancy

Peter D. Creigh

and David N. Herrmann

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 12 June 2021

Charcot-Marie-Tooth neuropathies (CMT) represent the most common hereditary neuropathies and can affect men and women from infancy to adulthood. There are no effective or FDA approved pharmacologic treatments aimed at disease modification for any form of CMT, so the primary focus of clinical care is on symptomatic treatment, maintaining functionality, and limiting secondary injury. CMT does not in general appear to affect a woman’s ability to carry a pregnancy. However, having CMT does increase the risk of delivery related complications (operative delivery, fetal presentation anomalies and postpartum bleeding) and exacerbation of neurologic symptoms during pregnancy is possible. Therefore, understanding the risks and planning appropriately are crucial for all women with CMT considering pregnancy and their health care providers. Overall, with the appropriate medical care, most women with CMT who choose to become pregnant will have an uncomplicated pregnancy and deliver a healthy infant.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.